The brief

Analyst view

• YOLT-101, a PCSK9 base editor, showed 50% LDL-C and 76% PCSK9 reduction in Phase I trials.
• Raised $115M across Series B and C funding through May 2026.
• First in vivo base editor for cardiovascular disease to enter clinical trials in China and the U.S.

Technical approach

As reported

Base editing, not cutting

Single-letter DNA changes without double-strand breaks

Base editing converts one DNA letter to another without cutting both DNA strands, reducing immune activation and off-target edits compared to CRISPR cutting.

In vivo delivery

Editing happens inside living cells, in one dose

LNP delivery carries base-editing machinery to liver cells intravenously. Cells retain the edit permanently.

PCSK9 disruption

Permanently lowers cholesterol

Disrupting PCSK9 in liver cells increases LDL clearance, mimicking drugs but from one treatment.